Citigroup’s Insys Therapeutics, Inc. INSY Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2019
Q2
Sell
-9,423
Closed -$44K 7932
2019
Q1
$44K Buy
9,423
+2,988
+46% +$14.1K ﹤0.01% 6448
2018
Q4
$22K Sell
6,435
-2,901
-31% -$20.2K ﹤0.01% 6840
2018
Q3
$94K Buy
9,336
+6,269
+204% +$50K ﹤0.01% 5974
2018
Q2
$22K Sell
3,067
-2,144
-41% -$14.9K ﹤0.01% 6885
2018
Q1
$32K Sell
5,211
-48
-0.9% -$396 ﹤0.01% 6475
2017
Q4
$50K Sell
5,259
-8,510
-62% -$55.7K ﹤0.01% 6187
2017
Q3
$123K Buy
13,769
+4,373
+47% +$45.1K ﹤0.01% 5404
2017
Q2
$119K Sell
9,396
-171
-2% -$2.02K ﹤0.01% 5221
2017
Q1
$100K Sell
9,567
-54,347
-85% -$579K ﹤0.01% 5217
2016
Q4
$587K Buy
63,914
+32,964
+107% +$372K ﹤0.01% 4214
2016
Q3
$365K Buy
30,950
+12,439
+67% +$189K ﹤0.01% 4182
2016
Q2
$240K Sell
18,511
-4,309
-19% -$62.8K ﹤0.01% 4330
2016
Q1
$365K Buy
22,820
+14,197
+165% +$270K ﹤0.01% 4484
2015
Q4
$247K Sell
8,623
-21,822
-72% -$605K ﹤0.01% 4545
2015
Q3
$866K Buy
30,445
+5,552
+22% +$204K ﹤0.01% 3228
2015
Q2
$894K Sell
24,893
-385
-2% -$12K ﹤0.01% 3234
2015
Q1
$735K Sell
25,278
-4,930
-16% -$130K ﹤0.01% 3368
2014
Q4
$637K Buy
30,208
+11,556
+62% +$229K ﹤0.01% 3625
2014
Q3
$362K Buy
18,652
+16,048
+616% +$252K ﹤0.01% 3779
2014
Q2
$41K Sell
2,604
-4,558
-64% -$73.7K ﹤0.01% 5299
2014
Q1
$148K Sell
7,162
-2,132
-23% -$42.3K ﹤0.01% 4632
2013
Q4
$120K Buy
9,294
+9,270
+38,625% +$129K ﹤0.01% 5111
2013
Q3
$0 Buy
+24
New +$197 ﹤0.01% 7093

Other funds holding INSY

Citigroup's INSY Position: Q2 2019 in Review

Citigroup sold out of Insys Therapeutics, Inc. (INSY) in Q2 2019, closing a stake of 9,423 shares — an estimated $44K sold.

Citigroup first reported a position in INSY in Q3 2013 and held it in 23 quarters. The position peaked at $894K in Q2 2015. 16 funds tracked by Wall St. Rank hold INSY as of Q2 2019.

  • Citigroup reported no remaining Insys Therapeutics, Inc. position as of Q2 2019 after selling out during the quarter.
  • Citigroup sold 9,423 Insys Therapeutics, Inc. shares in Q2 2019, an estimated $44K.
  • Citigroup first reported a position in Insys Therapeutics, Inc. in Q3 2013 and held it in 23 quarters.
  • Citigroup's Insys Therapeutics, Inc. position peaked at $894K in Q2 2015.
  • 16 funds tracked by Wall St. Rank held Insys Therapeutics, Inc. as of Q2 2019.

Based on Citigroup's 13F filing for Q2 2019, filed 12 Aug 2019.